News

Among patients with primary hyperoxaluria and CKD, those with delayed CKD diagnosis were more likely to encounter greater healthcare burdens.

A study finds older adults with depression and comorbid anxiety show less improvement after accelerated theta burst stimulation.

Findings suggest having GERD incurs an 18% greater risk of a new AUD diagnosis, presenting an opportunity to discuss alcohol use with patients.

Saxena discusses lorundrostat’s efficacy in lowering systolic blood pressure regardless of additional antihypertensive medications.

This systematic review and meta-analysis highlights tildrakizumab’s efficacy in Asian patients versus the efficacy of other biologic options.

Right transcutaneous auricular VNS (taVNS) acutely increases food liking in patients with MDD, especially those with high anhedonia, a study found.

GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.

FDA launches the Commissioner’s National Priority Voucher program, expediting drug reviews for critical health needs.

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.

A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.

A study found no major differences in overall cancer risk among adalimumab, secukinumab, and ustekinumab for psoriasis.

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

This analysis highlights the impact of dermatology consultations on HS management within acute care settings.

Investigators estimate that replacing individually prescribed school-based devices with spare adrenaline autoinjectors could improve access for students.

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

A recent study from Duke University spotlighted papSCAR’s substantial association with both cardiovascular mortality and arrhythmia.

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

SelectION, Inc. has announced positive topline findings from its phase 1b proof-of-concept study assessing si-544 in those with psoriasis vulgaris.

Adults given an initial 0.5 mg intramuscular epinephrine dose were less likely to need further intervention than those receiving 0.3 mg, a study found.

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

JAK inhibitors have transformed the world of treatment for inflammatory disease, and views on their safety and efficacy have also transformed over the years.

The ACP Performance Measurement Committee reviewed 5 performance measures for CRC screening, ultimately only supporting 1 of them.